OXBO.F Stock Overview
A biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Oxford BioDynamics Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.15 |
| 52 Week High | UK£0.50 |
| 52 Week Low | UK£0.01 |
| Beta | 0.46 |
| 11 Month Change | 0% |
| 3 Month Change | 50.00% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| OXBO.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | -1.9% | 0.4% |
| 1Y | n/a | -0.5% | 22.9% |
Return vs Industry: Insufficient data to determine how OXBO.F performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how OXBO.F performed against the US Market.
Price Volatility
| OXBO.F volatility | |
|---|---|
| OXBO.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.8% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: OXBO.F's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine OXBO.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 53 | Jon Anthony Burrows | www.oxfordbiodynamics.com |
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and the United Kingdom. The company provides EpiSwitch, a proprietary technology platform that enables screening, evaluation, validation, and monitoring of 3D genomic biomarkers to diagnose patients. Its products include EpiSwitch Prostate Screening Test (PSE), a prostate cancer screening test; EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a blood test for predicting therapeutic response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling.
Oxford BioDynamics Plc Fundamentals Summary
| OXBO.F fundamental statistics | |
|---|---|
| Market cap | US$15.96m |
| Earnings (TTM) | -US$14.04m |
| Revenue (TTM) | US$780.05k |
20.5x
P/S Ratio-1.1x
P/E RatioIs OXBO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OXBO.F income statement (TTM) | |
|---|---|
| Revenue | UK£617.00k |
| Cost of Revenue | UK£361.00k |
| Gross Profit | UK£256.00k |
| Other Expenses | UK£11.36m |
| Earnings | -UK£11.11m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.055 |
| Gross Margin | 41.49% |
| Net Profit Margin | -1,800.32% |
| Debt/Equity Ratio | 0% |
How did OXBO.F perform over the long term?
See historical performance and comparison